Global Non-infectious Macular Edema Treatment Market to Reap Excessive Revenues by 2026

Anti-VEGF and corticosteroid therapies are considered to be the standard therapies for prevention of vision loss in patients in various indications of macular edema. The other drug types that are part of the macular edema treatment market are immunosuppressant and biologics, and many new treatment types are expected to be introduced as the market continues to grow. The outcomes of a recent market research has revealed the growth of the global non-infectious macular edema treatment market at a CAGR of 7.0% during the forecast period 2018-2026. The study also projects the market to reach a valuation of over US$ 17,200 Mn by the end of 2026.

Download Exclusive Sample Of This Report: https://www.researchmoz.us/enquiry.php?type=S&repid=1869344
Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.
A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.
Parent Indicators Healthcare
- Current expenditure on health, % of gross domestic product
- Current expenditure on health, per capita, US$ purchasing power parities (current prices, current PPPs)
- Annual growth rate of current expenditure on health, per capita, in real terms
- Out-of-pocket expenditure, % of current expenditure on health
- Out-of-pocket expenditure, per capita, US$ purchasing power parity (current prices, current PPPs)
- Physicians, Density per 1000 population (head counts)
- Nurses, Density per 1000 population (head counts)
- Total hospital beds, per 1000 population
- Curative (acute) care beds, per 1000 population
- Medical technology, Magnetic Resonance Imaging units, total, per million population
- Medical technology, Computed Tomography scanners, total, per million population
Approval of Intravitreal Implants and use of Immunosuppressants in the treatment of macular edema to trigger the growth of the market
Intravitreal Implants have been recently approved for the treatment of macular edema. Launch of three new products in 2014 viz., Eylea, Ozurdex and Iluvien, has led to the increased adoption of intravitreal medications in North America. The use of intravitreally injected medications was less common in North America and European countries as laser photocoagulation was the primary treatment before the launch of Lucentis in 2012. This increase in the adoption of Intravitreal therapies is a result of the launch of low dose high efficacy corticosteroid implants for Intravitreal use. Uptake of Intravitreal implants is increasing among patients, thus boosting the global demand for macular edema treatment.
Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/global-market-study-on-non-infectious-macular-edema-treatment-companies-to-launch-biosimilars-of-first-anti-vegf-lucentis-by-2020-report.html/toc
Immunosuppressant therapies are widely utilized coupled with corticosteroids. These are generally added to the corticosteroid regimen to eliminate the need for high doses of systemic steroids, or used alone as steroid-sparing agents in situations where steroids cannot be tolerated. For e.g., the three immunomodulators methotrexate (Rheumatrex), azathioprine (Imuran) and mycophenolate mofetil (MMF, Cellcept) are more effective in achieving disease quiescence and are well-tolerated by patients. These work as an efficient treatment type in the cure of non-infectious macular edema thereby proliferating demand in the global market.
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organisations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us

For More Reports Visit @ http://marketresearchlatestreports.blogspot.com/